Central Nervous System Diseases Clinical Trial
Official title:
Impact of Prophylactic Use of Dexmedetomidine on Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor: a Pilot Randomized Controlled Trial
Verified date | January 2021 |
Source | Capital Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Postoperative delirium is one of the most common serious complications after major surgery and is associated with undesirable consequences. Prevention of postoperative delirium is recommended in the clinical guidelines and consensus statements. Dexmedetomidine, a highly selective α2-adrenergic receptor agonist, has been investigated as a pharmacological intervention to prevent postoperative delirium. Several randomized controlled trials have shown that prophylactic use of low-dose dexmedetomidine may decrease the incidence of postoperative delirium in patients after cardiac and non-cardiac operations. However, neurosurgical patients are often excluded from previous studies due to potential consciousness and cognition impairment. The investigators design this pilot study aiming to clarify the feasibility and safety of use of low-dose dexmedetomidine for prevention of postoperative delirium in patients after intracranial operation for brain tumor.
Status | Completed |
Enrollment | 60 |
Est. completion date | December 21, 2020 |
Est. primary completion date | December 12, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients after elective intracranial operation for brain tumor under general anesthesia and who are admitted to the ICU directly from the operating room or postoperative care unit. Exclusion Criteria: - age under 18 years; - admitted to the ICU after 22:00 PM; - medical records documented preoperative history of mental or cognitive disorders including schizophrenia, epilepsy, Parkinsonism, or dementia; - medical records documented inability to communicate in the preoperative period due to coma or language barrier; - history of drug abuse of psychoactive and anesthetic drugs; - known preoperative severe bradycardia (lower than 50 beats/min), sick sinus syndrome, second- or third-degree atrioventricular block, or left ventricular ejection fraction lower than 30%; - serious hepatic dysfunction defined as Child-Pugh class C; - severe renal dysfunction requiring renal replacement therapy before the surgery; - allergies to ingredients or components of dexmedetomidine hydrochloride; - American Society of Anesthesiologists classification of IV to VI; - moribund condition with low likelihood of survival for more than 24 hours; - pregnancy or lactation women; - current enrollment in another clinical trial; - refusal to participate. |
Country | Name | City | State |
---|---|---|---|
China | ICU, Beijing Tiantan Hospital, Capital Medical University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Capital Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of study agent interruption during the study | Predicted adverse events in the present study included bradycardia (defined as heart rate lower than 50 beats/min), hypotension (defined as systolic blood pressure lower than 90 mmHg), tachycardia (defined as heart rate greater than 100 beats/min), hypertension (defined as systolic blood pressure greater than 160 mmHg) and hypoxemia (defined as pulse oxygen saturation lower than 90%). The treatment of adverse events was determined by the responsible attending ICU physicians, who could stop the study agent infusion when the treatment failure or other conditions deemed necessary. | From the start of study agent infusion to postoperative day 1 | |
Secondary | Time from the end of operation to randomization | Time from the end of operation to randomization | From the end of operation until the randomization, assessed up to 24 hours | |
Secondary | Duration of study agent infusion | Duration of study agent infusion | From the start of study agent infusion to postoperative day 1 | |
Secondary | Incidence of adverse events from the start of study agent infusion until 24 hours or until ICU discharge | Include bradycardia (defined as heart rate lower than 55 beats/min), hypotension (defined as systolic blood pressure lower than 90 mmHg), and hypoxemia (defined as pulse oxygen saturation lower than 90%) | From the start of study agent infusion to postoperative day 1 | |
Secondary | Non-delirium complications | Include airway obstruction and apnea, respiratory failure, cardiac events, coma, epilepsy, cerebral hemorrhage or infarction, renal injury and infection | From the start of study agent infusion to postoperative day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05778279 -
Role of New High Resolution Ultrasonographic Modalities for Diagnosis of Fetal Nervous System Anomalies
|
||
Completed |
NCT00116337 -
Spinal Cord Stimulation to Restore Cough
|
N/A | |
Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
Recruiting |
NCT05590884 -
Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age
|
Phase 2 | |
Recruiting |
NCT06010823 -
Safety and Efficacy Evaluation of the Robotic Enhanced Error Training of Upper Limb Function in Post-stroke and Post TBI Participants
|
N/A | |
Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
Completed |
NCT01211873 -
Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions
|
Phase 3 | |
Completed |
NCT00395460 -
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients
|
Phase 3 | |
Terminated |
NCT03270189 -
Effect of the Visual Information Change in Functional Dystonia
|
N/A | |
Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
Recruiting |
NCT05968976 -
Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET
|
N/A | |
Not yet recruiting |
NCT05892510 -
Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke
|
Phase 2/Phase 3 | |
Suspended |
NCT04912115 -
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
|
Phase 2 | |
Completed |
NCT03994822 -
pRESET for Occlusive Stroke Treatment
|
N/A | |
Completed |
NCT04283253 -
Predictors of Response in Chronic Stroke
|
N/A | |
Completed |
NCT02684825 -
Detection of Silent Atrial Fibrillation aFter Ischemic StrOke
|
N/A | |
Completed |
NCT02368223 -
Feasibility of the Portable YouGrabber System
|
N/A | |
Completed |
NCT05815836 -
Precision Medicine in Stroke
|
||
Completed |
NCT01445639 -
Dexmedetomidine in Patients After Intracranial Surgery
|
Phase 4 | |
Completed |
NCT00995215 -
Sub-study to Spinal Cord Stimulation to Restore Cough
|
N/A |